Sanofi Says Acoziborole Winthrop for Sleeping Sickness Received Positive CHMP Opinion

MT Newswires Live02-27 20:09

Sanofi (SNY) said Friday the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion for Acoziborole Winthrop to treat of both early and advanced-stage gambiense sleeping sickness in patients aged 12 years and older.

The recommendation for Acoziborole Winthrop as a three-tablet, single-dose oral treatment, granted under an accelerated assessment procedure intended for countries outside the European Union, is expected to facilitate approval in the Democratic Republic of Congo and lead to an update of the World Health Organization's treatment guidelines for sleeping sickness, Sanofi said.

The positive opinion for Acoziborole Winthrop, which was co-developed by the Drugs for Neglected Diseases initiative, was based on a phase 2/3 study showing up to 96% success rates at 18 months across both early and advanced stages of T.b. gambiense, the company said.

The company said that it will donate the medicine to the WHO through its philanthropic arm Foundation S.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614858487?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 20:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614858487","market":"fut","top_or_hot":-1,"title":"Sanofi Says Acoziborole Winthrop for Sleeping Sickness Received Positive CHMP Opinion","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> (SNY) said Friday the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion for  Acoziborole Winthrop to treat of both early and advanced-stage gambiense sleeping sickness in patients aged 12 years and older.</p><p>The recommendation for Acoziborole Winthrop as a three-tablet, single-dose oral treatment, granted under an accelerated assessment procedure intended for countries outside the European Union, is expected to facilitate approval in the Democratic Republic of Congo and lead to an update of the World Health Organization's treatment guidelines for sleeping sickness, <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> said.</p><p>The positive opinion for Acoziborole Winthrop, which was co-developed by the Drugs for Neglected Diseases initiative, was based on a phase 2/3 study showing up to 96% success rates at 18 months across both early and advanced stages of T.b. gambiense, the company said.</p><p>The company said that it will donate the medicine to the WHO through its philanthropic arm Foundation S.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi Says Acoziborole Winthrop for Sleeping Sickness Received Positive CHMP Opinion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi Says Acoziborole Winthrop for Sleeping Sickness Received Positive CHMP Opinion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-27 20:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> (SNY) said Friday the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion for  Acoziborole Winthrop to treat of both early and advanced-stage gambiense sleeping sickness in patients aged 12 years and older.</p><p>The recommendation for Acoziborole Winthrop as a three-tablet, single-dose oral treatment, granted under an accelerated assessment procedure intended for countries outside the European Union, is expected to facilitate approval in the Democratic Republic of Congo and lead to an update of the World Health Organization's treatment guidelines for sleeping sickness, <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> said.</p><p>The positive opinion for Acoziborole Winthrop, which was co-developed by the Drugs for Neglected Diseases initiative, was based on a phase 2/3 study showing up to 96% success rates at 18 months across both early and advanced stages of T.b. gambiense, the company said.</p><p>The company said that it will donate the medicine to the WHO through its philanthropic arm Foundation S.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2614858487","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614858487","pubTimestamp":1772194144,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Sanofi  said Friday the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion for  Acoziborole Winthrop to treat of both early and advanced-stage gambiense sleeping sickness in patients aged 12 years and older.The recommendation for Acoziborole Winthrop as a three-tablet, single-dose oral treatment, granted under an accelerated assessment procedure intended for countries outside the European Union, is expected to facilitate approval in the Democratic Republic of Congo and lead to an update of the World Health Organization's treatment guidelines for sleeping sickness, Sanofi said.The positive opinion for Acoziborole Winthrop, which was co-developed by the Drugs for Neglected Diseases initiative, was based on a phase 2/3 study showing up to 96% success rates at 18 months across both early and advanced stages of T.b. gambiense, the company said.The company said that it will donate the medicine to the WHO through its philanthropic arm Foun","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4087":"商业印刷","CHMP":"冠军工业","BK4007":"制药","SNY":"赛诺菲安万特","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","SNYNF":"Sanofi","BK4588":"碎股"},"translate_title":"赛诺菲表示Acoziborole Winthrop治疗昏睡病获得了CHMP的积极意见","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CHMP":1.5,"SNY":1,"SNYNF":1.5},"content_text":"Sanofi (SNY) said Friday the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion for  Acoziborole Winthrop to treat of both early and advanced-stage gambiense sleeping sickness in patients aged 12 years and older.The recommendation for Acoziborole Winthrop as a three-tablet, single-dose oral treatment, granted under an accelerated assessment procedure intended for countries outside the European Union, is expected to facilitate approval in the Democratic Republic of Congo and lead to an update of the World Health Organization's treatment guidelines for sleeping sickness, Sanofi said.The positive opinion for Acoziborole Winthrop, which was co-developed by the Drugs for Neglected Diseases initiative, was based on a phase 2/3 study showing up to 96% success rates at 18 months across both early and advanced stages of T.b. gambiense, the company said.The company said that it will donate the medicine to the WHO through its philanthropic arm Foundation S.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614858487","isCrawlerRequest":true}